scPharmaceuticals (NASDAQ:SCPH) Earns “Buy” Rating from HC Wainwright

scPharmaceuticals (NASDAQ:SCPH)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They currently have a $18.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 427.86% from the stock’s previous close.

Separately, Craig Hallum lowered their price objective on scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday.

scPharmaceuticals Stock Performance

Shares of NASDAQ:SCPH traded down $0.50 during midday trading on Thursday, reaching $3.41. 2,961,492 shares of the company’s stock traded hands, compared to its average volume of 259,608. scPharmaceuticals has a one year low of $3.24 and a one year high of $6.71. The stock has a 50 day moving average of $4.53 and a 200 day moving average of $4.50. The company has a debt-to-equity ratio of 4.32, a quick ratio of 3.66 and a current ratio of 4.84. The company has a market cap of $170.60 million, a price-to-earnings ratio of -2.19 and a beta of 0.15.

scPharmaceuticals (NASDAQ:SCPH) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.44) EPS for the quarter, meeting analysts’ consensus estimates of ($0.44). scPharmaceuticals had a negative return on equity of 201.84% and a negative net margin of 252.18%. The company had revenue of $8.05 million during the quarter, compared to analyst estimates of $8.04 million. As a group, equities research analysts anticipate that scPharmaceuticals will post -1.34 EPS for the current fiscal year.

Institutional Trading of scPharmaceuticals

Several institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets grew its holdings in shares of scPharmaceuticals by 116.9% during the third quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company’s stock worth $26,000 after buying an additional 3,101 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in scPharmaceuticals in the third quarter valued at about $57,000. MetLife Investment Management LLC lifted its position in scPharmaceuticals by 135.0% in the third quarter. MetLife Investment Management LLC now owns 16,974 shares of the company’s stock valued at $77,000 after buying an additional 9,752 shares during the last quarter. Captrust Financial Advisors lifted its position in shares of scPharmaceuticals by 32.2% during the third quarter. Captrust Financial Advisors now owns 18,539 shares of the company’s stock worth $85,000 after purchasing an additional 4,513 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of scPharmaceuticals during the first quarter worth about $90,000. 89.52% of the stock is owned by institutional investors and hedge funds.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.